{"disease":{"id":"sepsis-induced-coagulopathy","name":"sepsis induced coagulopathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06078839","title":"Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":778,"lead_sponsor_name":"Xu Li","has_results":false},{"nct_id":"NCT06994312","title":"The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":282,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06379126","title":"The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":210,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}